0.00Open0.05Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover57.90%IV27.50%PremiumSep 20, 2024Expiry Date0.00Intrinsic Value100Multiplier59DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.2107Delta0.6191Gamma40.00Leverage Ratio-0.0012Theta0.0006Rho8.43Eff Leverage0.0023Vega
Genprex Stock Discussion
NEWS
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Genprex announced the first patient dosing in its Phase 1 Acclaim-3 clinical study of Reqorsa Immunogene Therapy in combination with Tecentriq to treat extensive-stage small cell lung cancer (ES-SCLC). This trial, which aims to determine the maximum tolerated dose for a Phase 2 expansion expected in the second half of 2024, ...
📊⚡️📊
No comment yet